Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 15/20 | 0.53 |
| ▸ | PLAU | P00749 | 6/20 | 0.44 |
| ▸ | F2 | P00734 | 5/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25933322 | 0.93 | PDGFRA (0.45) | ELANEPLAUF2PDGFRACDK5 | |
| SCHEMBL18511974 | 0.90 | ELANE (0.65) | ELANEPLAUF2CTRB1L3MBTL1 | |
| SCHEMBL8738218 | 0.88 | PDGFRA (0.48) | ELANEPDGFRACDK5TYRO3USP30 | |
| SCHEMBL31182074 | 0.88 | PDGFRA (0.45) | ELANEPDGFRACDK5TYRO3USP30 | |
| SCHEMBL793283 | 0.87 | ELANE (0.55) | ELANEPLAUF2 | |
| SCHEMBL21801028 | 0.87 | PDGFRA (0.42) | ELANEPDGFRACDK5TYRO3USP30 | |
| SCHEMBL29850456 | 0.87 | PDGFRA (0.42) | ELANEPDGFRACDK5TYRO3USP30 | |
| SCHEMBL21801235 | 0.84 | PDGFRA (0.40) | ELANEPDGFRACDK5TYRO3USP30 | |
| SCHEMBL2811245 | 0.83 | ELANE (0.43) | ELANEPLAUF2CTRB1KLKB1 | |
| SCHEMBL4300088 | 0.82 | ELANE (0.55) | ELANEPLAUF2PDGFRACDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12172975-B2 | 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| EP-3849968-B1 | 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3849968-B1 | 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220380335-A1 | 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) | BRISTOL MYERS SQUIBB CO (US) | 2022-12-01 | — | — | US | disclosed |
| CN-112673000-A | 1H-indazole carboxamides as receptor interacting protein kinase 1 inhibitors (RIPK1) | 百时美施贵宝公司 | 2021-04-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12172975-B2 | 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1) | RIPK1, RIPK3, RIPK2 | ELANE 4744/4885PLAU 4329/4885F2 4783/4885 |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ELANE 892/4885PLAU 4557/4885F2 4794/4885 |
| US-20220380335-A1 | 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) | RIPK1, RIPK3, RIPK2 | ELANE 4744/4885PLAU 4329/4885F2 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.